TERN THERAPEUTICS

We’re pioneering a new approach to the development of one-time AAV gene therapies for rare diseases.

Learn more ⟶

A smiling boy in a wheelchair playing a yellow ukulele outdoors.

Our lead candidate, TTX-381, is currently in clinical testing for the treatment of ocular manifestations of CLN2, a form of Batten disease.

Learn more ⟶

News

Blog

Dec 2, 2025

Tern Therapeutics Selected by US FDA to Participate in the CDRP Program to Expedite CMC Development of TTX-381 to Treat Vision Loss in CLN2 Disease

Dec 2, 2025

Dec 2, 2025

Nov 5, 2025

Tern Therapeutics Presents Positive Twelve-Month Data from Dose Escalation Cohorts in Phase I/II Trial of TTX-381

Nov 5, 2025

Nov 5, 2025

Oct 27, 2025

Tern Therapeutics Opens New TTX-381 Clinical Trial Site at UKE in Hamburg, Germany

Oct 27, 2025

Oct 27, 2025

Jul 24, 2025

U.K. MHRA Awards Tern Therapeutics Innovation Passport for TTX-381 to Accelerate Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

Jul 24, 2025

Jul 24, 2025

Jun 3, 2025

Tern Therapeutics Receives US FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

Jun 3, 2025

Jun 3, 2025

Apr 8, 2025

Tern Therapeutics Receives US FDA Fast Track Designation for TTX-381 Gene Therapy for the Treatment of the Ocular Manifestations of CLN2 Disease

Apr 8, 2025

Apr 8, 2025

Feb 27, 2025

Tern Therapeutics Issues CLN2 Batten Community Letter

Feb 27, 2025

Feb 27, 2025

Feb 10, 2025

Tern Therapeutics Advances Pipeline and Presents Positive Clinical Data for TTX-381 and TTX-181 Gene Therapies for CLN2 Batten Disease at 21st Annual WORLDSymposiumᵀᴹ

Feb 10, 2025

Feb 10, 2025

Aug 27, 2024

Tern Therapeutics Launches with $15 Million Financing and Pipeline in CLN2 Batten Disease

Aug 27, 2024

Aug 27, 2024

VIEW ALL

Patients and their families are at the core of everything we do.

SAVING VISION  |  IMPROVING LIVES